Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2012 Jan 25;10:15. doi: 10.1186/1479-5876-10-15

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright ©2012 Qin et al; BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Silencing ERK1 and/or ERK2 reduces protein levels of upstream kinases after 4 days including BRAF, CRAF, and phospho MEK; while PD0325901 or PLX4032 exposure variably influences these kinases, with less to no effects of any treatments on BRAF mRNA levels. A. Western blot of upstream kinases in A375 cells 4 days after treatment with shRNAs (left side panel), or after exposure to PD0325901 (1 μM) or PLX4032 (5 μM) on right side panel. GAPDH confirms equivalent protein loading. B. BRAF mRNA levels after 4 days of exposure to PD0325901 orPLX4032 (upper panel); or after treatment with shRNAs (lower panel). Histograms represent the means +/- SD based on three independent experiments.